Pharmacokinetic and pharmacodynamic interaction be mexiletine and propafenone in human beings

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 1, 2000, Pages 44-57

  Labbé, Line ^a,b,c,d   O'Hara, Gilles ^a,b,c,d   Lefebvre, Michel ^a,b,c,d   Lessard, Étienne ^a,b,c,d   Gilbert, Marcel ^a,b,c,d   Adedoyin, Adedayo ^a,b,c,d   Champagne, Jean ^a,b,c,d   Hamelin, Bettina ^a,b,c,d   Turgeon, Jacques ^a,b,c,d  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYMEXILETINE; 4 HYDROXYMEXILETINE; 5 HYDROXYPROPAFENONE; AMIODARONE; ANTIARRHYTHMIC AGENT; BALMINIL DM; CIPROFLOXACIN; CYTOCHROME P450 3A4; DEBRISOQUINE; DEBRISOQUINE 4 HYDROXYLASE; DEPROPYLPROPAFENONE; DEXTROMETHORPHAN; DISOPYRAMIDE; HYDROXYMETHYLMEXILETINE; MEXILETINE; PHENACETIN O DEETHYLASE; PROPAFENONE; QUINIDINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; HEART ARRHYTHMIA; HUMAN; MALE; METABOLIC INHIBITION; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PR INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; RR INTERVAL;

ADMINISTRATION, ORAL; ADULT; ANTI-ARRHYTHMIA AGENTS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; GENOTYPE; HUMANS; MALE; MEXILETINE; MIXED FUNCTION OXYGENASES; PHENOTYPE; PROPAFENONE; REFERENCE VALUES;

EID: 0033856015     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.108023     Document Type: Article

References (50)

1. Mexiletine
2. Mexiletine in the treatment of resistant ventricular tachycardia: Enhancement of efficacy and reduction of dose-related side effects by combination with quinidine
3. Combination of disopyramide and mexiletine for better tolerance and additive effects for treatment of ventricular arrhythmias
4. Combined mexiletine and amiodarone treatment of refractory recurrent ventricular tachycardia
5. Propafenone-mexiletine combination for the treatment of sustained ventricular tachycardia
6. Stereoselective disposition of mexiletine in man
7. Effect of cigarette smoking on mexiletine kinetics
8. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man
9. Isolation and structural characterization by spectroscopic methods of two glucuronide metabolites of mexiletine after N-oxidation and deamination
10. Role du CYP1A2 dans la pharmacocinetique de la mexiletine chez l'humain [thesis]
11. Inhibition of theophylline metabolism by mexiletine in young male and female non-smokers
12. Influence of mexiletine on caffeine elimination
13. The metabolic fate of 2H-labelled propafenone in man
14. In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone
15. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: Molecular base for interaction potential and variable disposition of active metabolites
16. Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs
17. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population
18. Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection
19. Salivary analysis for determination of dextromethorphan metabolic phenotype
20. Determination of dextromethorphan and metabolites in human plasma and urine by high-performance liquid chromatography with fluorescence detection
21. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification
22. 1795 in exon 3 generates a premature stop codon
23. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine
24. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology
25. Improved high-performance liquid chromatographic assay for the stereoselective determination of mexiletine in plasma
26. Nonlinear kinetics of propafenone metabolites in healthy man
27. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma leveltime curve
28. Absorption, distribution and elimination of mexiletine
29. Interindividual variations in drug disposition: Clinical implications and methods of investigation
30. Accuracy of four automatic QT measurement techniques in cardiac patients and healthy subjects
31. An analysis of the time-relations of electrocardiograms
32. Interaction between propranolol and propafenone in healthy volunteers
33. Drug interaction between propafenone and metoprolol
34. Mexiletine metabolism in vitro by human liver
35. Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes
36. Involvement of CYP1A2 in mexiletine metabolism
37. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking
38. Quinolone antibacterial agents: Relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2
39. Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance
40. Theophylline toxicity after propafenone treatment: Evidence for drug interaction
41. Propafenone-theophylline interaction
42. Rifampicin lowers plasma concentrations of propafenone and its antiarrhythmic effect
43. Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification
44. Propafenone
45. Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone
46. Effects of propafenone on calcium current in guinea-pig ventricular myocytes
47. Potassium channel blocking properties of propafenone in rabbit atrial myocytes
48. Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinje fibers
49. Lack on clinically significant beta-blocking effect of propafenone
50. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone